Alteogen Registers Keytruda SC Composition Patent in Europe
Patent for Combination of ALT-B4 and Pembrolizumab Composition
Protected Until 2040; Up to 5 Years Additional Protection Possible Through SPC
Alteogen announced on September 23 that its composition patent for a subcutaneous injection formulation combining its hyaluronidase platform 'Hybrozyme'–based ALT-B4 (ingredient name: berahyaluronidase alpha) with Keytruda (ingredient name: pembrolizumab) has been registered with the European Patent Office (EPO).
This patent will be protected until 2040. In consideration of the time required for regulatory approval, it is also eligible for a Supplementary Protection Certificate (SPC), which allows for a maximum extension of up to five years.
Previously, Alteogen also registered a patent for a Keytruda subcutaneous injection composition in the United States. With the registration of this European patent, the scope of protection for the Keytruda SC composition patent now extends to both the United States and Europe.
Keytruda SC containing ALT-B4 has been gaining regulatory approvals and expanding its market to the United States, Europe, Canada, Korea, and Japan. Recently, Alteogen received the first milestone payment of USD 25 million (approximately KRW 3.38 billion) out of a total of USD 1 billion (approximately KRW 1.3539 trillion) in sales milestones under its contract with Merck & Co., Inc. (MSD) of the United States. Additional milestone payments and royalties are expected depending on future sales performance.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An Alteogen representative said, "Following the United States, we have now secured the composition patent combining ALT-B4 and pembrolizumab in Europe as well. We will continue to secure intellectual property rights for material, composition, manufacturing, and fixed-dose combination patents to underpin stable commercialization."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.